Jian Li

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review

Colistin Resistance in <i>Acinetobacter baumannii</i> Is Mediated by Complete Loss of Lipopolysaccharide Production

Structure−Activity Relationships of Polymyxin Antibiotics

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

Heteroresistance to Colistin in Multidrug-Resistant <i>Acinetobacter baumannii</i>

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy

Pharmacology of Polymyxins: New Insights into an ‘Old‘ Class of Antibiotics

Colistin in the 21st century

iLearn: an integrated platform and meta-learner for feature engineering, machine-learning analysis and modeling of DNA, RNA and protein sequence data